Table 2.
Medical and device therapies received among the percutaneous left ventricular assist device and non-percutaneous left ventricular assist device groups
| Therapy | pVAD (n = 13) | Non-pVAD (n = 18) | P value |
|---|---|---|---|
| ACE inhibitor or ARB (%) | 11 (84.6) | 14 (77.8) | 1.00 |
| Beta-blockers (%) | 12 (92.3) | 18 (100) | 0.42 |
| Failed AAD (%) | 13 (100) | 17 (94.4) | 1.00 |
| Mean number of failed AADsa | 2.0 | 2.0 | 0.49 |
| Receiving amiodarone (%) | 6 (46.2) | 15 (83.3) | 0.52 |
| Mean number of ICD shocks 30 days prior | 6.8 | 3.9 | 0.07 |
| ICD (%) | 11 (84.6) | 18 (100) | 0.17 |
| Biventricular pacing (%) | 2 (15.4) | 3 (16.7) | 1.00 |
| Prior catheter ablation | 6 (46.2) | 7 (38.9) | 0.73 |
Proportions are presented as n (%) and continuous variables are presented as means ± standard deviation.
AAD, anti-arrhythmic drug; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ICD, implantable cardioverter defibrillator; pVAD, percutaneous ventricular assist device.
aVariable (median) is non-normally distributed and comparisons between the two groups utilized the Mann–Whitney U test.